How Delhi HC’s post-expiry patent revocation ruling could impact India’s generic drug market, ETLegalWorld
Illustrative image The Delhi High Court’s division bench ruling in Boehringer Ingelheim v. Controller of Patents, upholding the maintainability of section 64 revocation petitions even post-patent expiry and alongside section 107 invalidity defenses in infringement suits, could reshape India’s USD 50 billion pharma market by tilting the balance toward generics and intensifying scrutiny on innovator […]










